Abstract
Background The Prostate Imaging Reporting & Data System (PI-RADS), based on multiparametric MRI (mpMRI), is widely used for the detection of clinically significant prostate cancer (csPCa, Gleason Grade Group (GG≥2)). However, its diagnostic accuracy can be impacted by variability in interpretation. Restriction Spectrum Imaging (RSI), an advanced diffusion-weighted technique, offers a standardized, quantitative approach for detecting csPCa, potentially enhancing diagnostic consistency and performing comparably to expert-level assessments.
Purpose To evaluate whether combining maximum RSI-derived restriction scores (RSIrs-max) with deep learning (DL) models can enhance patient-level detection of csPCa compared to using PI-RADS or RSIrs-max alone.
Materials and Methods Data from 1,892 patients across seven institutions were analyzed, selected based on MRI results and biopsy-confirmed diagnoses. Two deep learning architectures, 3D-DenseNet and 3D-DenseNet+RSI (incorporating RSIrs-max), were developed and trained using biparametric MRI (bpMRI) and RSI data across two data splits. Model performance was compared using the area under the receiver operating characteristic curve (AUC) for patient-level csPCa detection, using PI-RADS performance for clinical reference.
Results Neither RSIrs-max nor the best DL model combined with RSIrs-max significantly outperformed PI-RADS interpretation by expert radiologists. However, when combined with PI-RADS, both approaches significantly improved patient-level csPCa detection, with AUCs of 0.79 (95% CI: 0.74-0.83; P=.005) for combination of RSIrs-max with PI-RADS and 0.81 (95% CI: 0.76-0.85; P<.001) for combination of best DL model with PI-RADS, compared to 0.73 (95% CI: 0.68-0.78) for PI-RADS alone.
Conclusion Both RSIrs-max and DL models demonstrate comparable performance to PI-RADS alone. Integrating either model with PI-RADS significantly enhances patient-level detection of csPCa compared to using PI-RADS alone.
Summary Statement RSIrs-max and deep learning models match the performance of expert PI-RADS in patient-level csPCa detection and combining either with PI-RADS yields a significant improvement over PI-RADS alone.
Key Points
In a study of 1,892 patients from seven institutions undergoing MRI and biopsy for prostate cancer, RSIrs-max and the DL model (AUC, 0.75 (P=.59) and 0.78 (P=.09)) performed comparably to expert-level PI-RADS scores (AUC, 0.73).
Including prostate auto-segmentation improved the DL model (AUC, 0.68 (P=.01) vs 0.72 (P=.60)).
Combining RSIrs-max or the DL model (AUC, 0.79 (P=.005) and 0.81 (P <.001)) with PI-RADS statistically significantly outperformed PI-RADS alone (AUC, 0.73).
Competing Interest Statement
DJAM reports a clinical advisor role for Stratagen Bio and an ad hoc consultant role for Guerbet and Promaxo. SAW was supported by funding from the ARRS Scholarship for professional development and has received investigator-initiated research grants (paid to the institution) from Siemens. Sophia C. Kamran spouse is employed by Sanof. AMD is a founder of and holds equity interest in CorTechs Labs and serves on its scientific advisory board. He is also a member of the Scientific Advisory Board of Healthlytix and receives research funding from General Electric Healthcare (GEHC). Rebecca Rakow-Penner Human Longevity Inc: Consultant, Cortech Labs: Stock options, Curemetrix: Stock options, consultant Imagine Scientific, advisory board. SBIR GE Healthcare, research agreement Bayer consultant. Michael Liss Founder/President of Oncobiomix with no relation to this manuscript. TMS reports honoraria from Multimodal Imaging Services Corporation, Varian Medical Systems, Janssen, and WebMD; he has an equity interest in CorTechs Labs, Inc. and serves on its Scientific Advisory Board. These companies might potentially benefit from the research results. The terms of the above arrangements have been reviewed and approved by the University of California San Diego in accordance with its conflict-of -interest policies. The remaining authors have no conflicts of interest to disclose.
Funding Statement
National Institutes of Health, Grant/Award Numbers: NIH/NIBIB K08EB026503, NIHUL1TR000100; American Society for Radiation Oncology; Prostate Cancer Foundation: PCF20YOUN01; Department of Defense, Grant/Award Number: DOD/CDMRPPC220278
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the University of California San Diego gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
